The Pharmaletter

Myricx Bio

A UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

Company Overview

Want to Update your Company's Profile?


More Myricx Bio news >